Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Consolidation Docetaxel in Stage III NSCLC
NCT00216125Phase 3Completed
- Start
- Feb 2002
- Primary completion
- Jun 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Consolidation Docetaxel with Observation Only (2 arms). Primary endpoint: Overall Survival. Started Feb 2002; status: completed.
02
Drugs
docetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00216125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00216125.